2004
DOI: 10.1128/cmr.17.4.926-941.2004
|View full text |Cite
|
Sign up to set email alerts
|

Antibody Therapy in the Management of Shiga Toxin-Induced Hemolytic Uremic Syndrome

Abstract: Hemolytic uremic syndrome (HUS) is a disease that can lead to acute renal failure and often to other serious sequelae, including death. The majority of cases are attributed to infections with Escherichia coli, serotype O157:H7 strains in particular, which cause bloody diarrhea and liberate one or two toxins known as Shiga toxins 1 and 2. These toxins are thought to directly be responsible for the manifestations of HUS. Currently, supportive nonspecific treatment is the only available option for the management … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
83
0
3

Year Published

2005
2005
2011
2011

Publication Types

Select...
6
2
2

Relationship

2
8

Authors

Journals

citations
Cited by 109 publications
(86 citation statements)
references
References 138 publications
(148 reference statements)
0
83
0
3
Order By: Relevance
“…The five main subtypes are stx 2 , stx 2c , stx 2d , stx 2e , and stx 2f (22,26,30). The BLAST searches revealed that the primer sequences for this assay matched stx 2 and stx 2c (GenBank accession no.…”
Section: Discussionmentioning
confidence: 99%
“…The five main subtypes are stx 2 , stx 2c , stx 2d , stx 2e , and stx 2f (22,26,30). The BLAST searches revealed that the primer sequences for this assay matched stx 2 and stx 2c (GenBank accession no.…”
Section: Discussionmentioning
confidence: 99%
“…Combined with the ease of subcutaneous injection, the approach presented here represents a highly practical strategy for a large-scale prophylactic response to anthrax exposure, including antibiotic-resistant strains (3). Studies are under way to determine whether PEGylated, high-affinity antibody fragments can be employed for protection or therapy against other bacterial agents where pathogenicity is intimately associated with toxin production, e.g., Shiga toxin-producing hemolytic E. coli (49), other microbial pathogens, and, finally, viral infections. If that proves to be the case, PEGylated antibodies will likely represent a practical and rapidly deployable therapeutic avenue for combating emerging infections.…”
Section: Discussionmentioning
confidence: 99%
“…Several therapeutic approaches that attempted to neutralize Stx either in the gut or in the circulation include the use of synthetic Gb 3 analogues, genetically manipulated bacteria expressing Gb 3 , and Stx-specific neutralizing antibodies (32). The systemic administration of Stx-specific neutralizing antibodies, we believe, is currently the most promising approach for prevention of Stx-mediated systemic complications including HUS.…”
mentioning
confidence: 99%